newest glp 1 medication Ro Launches Wegovy® Pill Through Integration with Novo Nordisk The first ever FDA-approved GLP-1

market spans diabetic peripheral neuropathy (DPN) and hereditary transthyretin polyneuropathy (hATTR-PN)together a multi-billion opportunity with very different evidence and access models

Nslund, E., Gutniak, M., Skogar, S., Rssner, S

Both are studied for cell migration and actin regulation in tissue-repair models

doi:10.1038/eye.2014.144 36

That matters in chronic conditions, where treatment can last for months or even years

However, anaesthetists must be aware that withholding the therapy in patients with type 2 diabetes mellitus may increase the risk of perioperative hyperglycaemia, which can, in turn, elevate the likelihood of postoperative complications, such as wound infections [22]